Nothing Special   »   [go: up one dir, main page]

MX2013005067A - Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato. - Google Patents

Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.

Info

Publication number
MX2013005067A
MX2013005067A MX2013005067A MX2013005067A MX2013005067A MX 2013005067 A MX2013005067 A MX 2013005067A MX 2013005067 A MX2013005067 A MX 2013005067A MX 2013005067 A MX2013005067 A MX 2013005067A MX 2013005067 A MX2013005067 A MX 2013005067A
Authority
MX
Mexico
Prior art keywords
receptor alpha
folate receptor
frî
subject
methods
Prior art date
Application number
MX2013005067A
Other languages
English (en)
Other versions
MX343607B (es
Inventor
Luigi Grasso
Daniel J O'shannessy
Shanhong Wan
Qimin Chao
Elizabeth Brooke Somers
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of MX2013005067A publication Critical patent/MX2013005067A/es
Publication of MX343607B publication Critical patent/MX343607B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona métodos y equipos para evaluar si un sujeto padece de un cáncer que expresa FRa, métodos y equipos para anticipar el progreso de un cáncer de ovario en un sujeto que padece de un cáncer que expresa FRa, métodos y equipos para evaluar el nivel de riesgo que tiene un sujeto de desarrollar un cáncer que expresa FRa, y métodos para estratificar a un sujeto con un cáncer que expresa FRa en grupos de terapia de cáncer. Los métodos implican determinar el nivel de receptor alfa de folato FRa que no está enlazado a una célula en una muestra derivada del sujeto, y comparar este nivel con el nivel de FRa en una muestra de control.
MX2013005067A 2010-11-05 2011-11-04 Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. MX343607B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41049710P 2010-11-05 2010-11-05
US201161508444P 2011-07-15 2011-07-15
PCT/US2011/059411 WO2012061759A2 (en) 2010-11-05 2011-11-04 Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers

Publications (2)

Publication Number Publication Date
MX2013005067A true MX2013005067A (es) 2013-07-02
MX343607B MX343607B (es) 2016-11-11

Family

ID=45003076

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016011546A MX368394B (es) 2010-11-05 2011-11-04 Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
MX2013005067A MX343607B (es) 2010-11-05 2011-11-04 Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016011546A MX368394B (es) 2010-11-05 2011-11-04 Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.

Country Status (14)

Country Link
US (1) US20120207771A1 (es)
EP (2) EP2635304B1 (es)
JP (2) JP6224456B2 (es)
KR (2) KR102057438B1 (es)
CN (2) CN103687618A (es)
AU (3) AU2011323124C1 (es)
BR (1) BR112013011072B1 (es)
CA (1) CA2816991C (es)
ES (2) ES2780192T3 (es)
IL (2) IL225871B (es)
MX (2) MX368394B (es)
RU (2) RU2764592C2 (es)
SG (3) SG10201509145XA (es)
WO (1) WO2012061759A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
HUE030854T2 (en) 2010-02-24 2017-06-28 Immunogen Inc Immunoconjugates against folate receptor 1 and their use
US20120189620A1 (en) * 2011-01-21 2012-07-26 Emory University Methods for treating non-functioning pituitary adenoma
WO2012119077A1 (en) * 2011-03-02 2012-09-07 Morphotek Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
MX346555B (es) 2011-04-01 2017-03-24 Immunogen Inc Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
SG10201605278PA (en) * 2011-07-15 2016-08-30 Eisai R&D Man Co Ltd Anti-folate receptor alpha antibodies and uses thereof
BR112014028306A2 (pt) * 2012-05-15 2018-04-17 Morphotek, Inc. métodos para tratamento de câncer gástrico.
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
MX2015017950A (es) * 2013-06-20 2016-05-10 Morphotek Inc Metodos para el tratamiento de cancer de ovario.
PT3038650T (pt) 2013-08-30 2021-08-25 Immunogen Inc Anticorpos e ensaios para a deteção do recetor de folato 1
KR20220136468A (ko) * 2013-10-08 2022-10-07 이뮤노젠 아이엔씨 항-folr1 면역접합체 투여 레지멘
LT3221357T (lt) 2014-11-20 2020-08-25 F. Hoffmann-La Roche Ag Bendros lengvosios grandinės ir naudojimo būdai
ES2835823T3 (es) 2014-11-20 2021-06-23 Hoffmann La Roche Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
CN107624071A (zh) 2015-04-17 2018-01-23 诺福泰克公司 肺癌治疗方法
RU2749865C2 (ru) 2015-09-17 2021-06-17 Иммьюноджен, Инк. Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
KR102708209B1 (ko) 2016-08-12 2024-09-20 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도
JP7072571B2 (ja) 2016-11-23 2022-05-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗葉酸受容体アルファ抗体およびその使用
CN107446021B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽5及其应用
CN107353325B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽1及其应用
CN107446020B (zh) * 2017-07-28 2019-10-01 中国药科大学 叶酸受体α特异性结合肽2及其应用
EP3679371A4 (en) * 2017-09-05 2021-06-16 Immunogen, Inc. METHOD OF DETECTING FOLATE RECEPTOR 1 IN A PATIENT SAMPLE
EP3749313A4 (en) 2018-02-07 2022-03-16 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED ANTIFOLATES AND USES THEREOF
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
JP7491573B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
US12048767B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
WO2019160735A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
CN111954681B (zh) * 2018-03-13 2022-12-06 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
CN114222756A (zh) 2019-04-29 2022-03-22 伊缪诺金公司 双互补位FR-α抗体和免疫缀合物
US20240226312A1 (en) * 2021-06-04 2024-07-11 Immunogen, Inc. Treatment of cancer in patients with soluble fr-alpha
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
ATE267877T1 (de) 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
CA2158642A1 (en) 1993-03-19 1994-09-29 Hubert Koster Dna sequencing by mass spectrometry via exonuclease degradation
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6933108B2 (en) * 1999-12-09 2005-08-23 The Regents Of The University Of California Methods and compositions for use in the treatment of filovirus mediated disease conditions
WO2002037112A2 (en) * 2000-11-01 2002-05-10 Mount Sinai Hospital Detection of ovarian cancer
US20100120078A1 (en) * 2001-08-16 2010-05-13 Tony Baker Urine Stabilization System
CA2466474C (en) * 2001-11-13 2012-10-09 Shire Biochem Inc. Compositions comprising spa-1, spa-2 and spa-3, polypeptides and related uses
WO2003091700A2 (en) * 2002-03-26 2003-11-06 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
WO2004082463A2 (en) * 2003-03-17 2004-09-30 Medical College Of Ohio Folate receptor gene modulation for cancer diagnosis and therapy
CA2526647A1 (en) 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies
JP2007512807A (ja) * 2003-10-28 2007-05-24 バイエル ヘルスケア アーゲー 悪性腫瘍の処置に対する応答予測のための方法および組成物
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
ATE460668T1 (de) * 2005-03-30 2010-03-15 Purdue Research Foundation Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
US8034549B2 (en) * 2006-02-09 2011-10-11 University Of South Florida Detection of cancer by elevated levels of BCL-2
CA2685300C (en) * 2006-06-01 2017-01-03 Mayo Foundation For Medical Education And Research Immunity to folate receptors
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7754698B2 (en) 2007-01-09 2010-07-13 Isis Pharmaceuticals, Inc. Modulation of FR-alpha expression
WO2009054939A2 (en) * 2007-10-19 2009-04-30 Cell Signaling Technology, Inc. Cancer classification and methods of use
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
US20110177525A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
US20140148350A1 (en) * 2010-08-18 2014-05-29 David Spetzler Circulating biomarkers for disease

Also Published As

Publication number Publication date
RU2017129266A3 (es) 2021-01-25
IL225871B (en) 2018-08-30
WO2012061759A3 (en) 2012-07-26
EP3130605B1 (en) 2020-01-08
IL260590B (en) 2020-01-30
SG10201509145XA (en) 2015-12-30
JP2013544354A (ja) 2013-12-12
US20120207771A1 (en) 2012-08-16
RU2017129266A (ru) 2019-02-04
KR20140024838A (ko) 2014-03-03
EP3130605A1 (en) 2017-02-15
JP6224456B2 (ja) 2017-11-01
CA2816991A1 (en) 2012-05-10
ES2780192T3 (es) 2020-08-24
AU2016203408A1 (en) 2016-06-16
RU2630608C2 (ru) 2017-09-11
RU2013125772A (ru) 2014-12-10
CN108562744A (zh) 2018-09-21
BR112013011072B1 (pt) 2021-02-02
KR20180137587A (ko) 2018-12-27
AU2011323124A1 (en) 2013-05-09
AU2018201760A1 (en) 2018-04-05
MX343607B (es) 2016-11-11
CA2816991C (en) 2020-06-09
CN103687618A (zh) 2014-03-26
IL225871A0 (en) 2013-06-27
WO2012061759A2 (en) 2012-05-10
ES2627061T3 (es) 2017-07-26
AU2011323124B2 (en) 2016-02-25
MX368394B (es) 2019-10-01
JP2018036270A (ja) 2018-03-08
EP2635304B1 (en) 2017-03-08
KR101931936B1 (ko) 2018-12-26
RU2764592C2 (ru) 2022-01-18
BR112013011072A2 (pt) 2017-06-20
AU2011323124C1 (en) 2016-09-22
KR102057438B1 (ko) 2019-12-20
JP6554152B2 (ja) 2019-07-31
SG189957A1 (en) 2013-06-28
SG10201701933XA (en) 2017-05-30
AU2018201760B2 (en) 2019-07-25
EP2635304A2 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
MX2013005067A (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
GB2503148A (en) Biomarker panels diagnostic methods and test kits for ovarian cancer
IN2013CN01129A (es)
GB2531881A (en) Method of isolating circulating tumor cells
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX367366B (es) Composiciones y metodos para diagnosticar tumores de tiroides.
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
WO2009120561A3 (en) Methods and gene expression signature for assessing growth factor signaling pathway regulation status
MX357119B (es) Microarn plasmáticos para la detección de cáncer colorrectal temprano.
MX340453B (es) Biomarcadores para cancer de pulmon.
WO2014028884A3 (en) Cancer diagnostics using biomarkers
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
NZ621733A (en) Lung cancer biomarkers and uses thereof
EA201370063A1 (ru) Фосфолипидом рака
EA201691499A1 (ru) Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям
BR112016018044A2 (pt) teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer
WO2012074904A3 (en) Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
WO2011113047A3 (en) Compositions and methods for characterizing breast cancer
NZ602840A (en) Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
MX2017009998A (es) Biomarcadores para cancer pancreatico.
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
NZ621638A (en) Dna methylation in colorectal and breast cancer diagnostic methods
WO2013171586A3 (en) Metabolite biomarkers for staging colorectal cancer

Legal Events

Date Code Title Description
FG Grant or registration